Administration of belimumab prior to standard immunosuppression in patients with early active lupus hinders accrual of new EULAR/ACR criteria within the first 12 months of treatment. Journal Abstract - Guideline Central

Administration of belimumab prior to standard immunosuppression in patients with early active lupus hinders accrual of new EULAR/ACR criteria within the first 12 months of treatment.

Published: 2025 Oct 22

Authors

, , , , , , , , , ,

Abstract

To evaluate the effect of early belimumab administration on disease progression in patients with early active SLE.

Keywords: Biologics, Cost of Illness, Lupus Erythematosus, Systemic

Source

Lupus science & medicine

Publication Type

Journal Article

Language

English

PubMed ID

41130615

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.